Navigation Links
MedImmune Celebrates Opening of New Pilot Lab at Gaithersburg Headquarters
Date:8/23/2007

New Facility Allows MedImmune to Meet Increasing Demands for Clinical Trial

Materials from Company's Expanding and Advancing Pipeline

GAITHERSBURG, Md., Aug. 23 /PRNewswire-FirstCall/ -- MedImmune today unveiled a new, state-of-the-art pilot lab facility located on the same Gaithersburg site as its headquarters. With its cutting-edge equipment and process automation systems, the facility will support MedImmune's expanding clinical product pipeline by providing additional capacity and flexibility.

At a ribbon-cutting event for the pilot lab held today at MedImmune, David M. Mott, president and chief executive officer, stated: "Completing this new facility is an important milestone, signaling our continued growth and success as a world-class biopharmaceuticals company. The opening of this facility, alongside the expansion work underway on our new biologics facility in Frederick, Maryland, reaffirms our leadership role within the state's biotechnology industry and demonstrates our ongoing commitment to the region."

The new pilot lab's 5,000 liters of bioreactor capacity will result in a four-fold increase in production capabilities. With the expanded facility, MedImmune will be able to produce clinical trial materials at a greater scale and in greater quantities, aiding in the testing of potential new products.

"This substantial increase in MedImmune's clinical production infrastructure supports our robust pipeline of product candidates," said Gail Folena-Wasserman, Ph.D., senior vice president, development. "The pilot lab facility is intended to meet our current and future needs, not just through its increased capacity but also through design flexibility, which efficiently allows us to produce multiple clinical products in the same space. We can drive efficiency and meet rigorous quality standards by incorporating the latest technology, including an advanced process control system."

In December 2006, the City of Gaithersburg approved the new pilot lab facility for occupancy. The facility will become the primary site for production of MedImmune's therapeutic proteins, replacing the existing Gaithersburg Manufacturing Development Facility (GMDF) where those clinical trial materials are currently produced. Material production is expected to begin in 2008, following the final stages of equipment validation. MedImmune plans to upgrade GMDF in the near future to provide added support for its development needs.

About MedImmune

MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious diseases, cancer and inflammatory diseases. With approximately 3,000 employees worldwide and headquarters in Maryland, MedImmune is wholly owned by AstraZeneca plc (NYSE: AZN). For more information, visit MedImmune's website at http://www.medimmune.com.


'/>"/>
SOURCE MedImmune
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. The Why Files celebrates decade of science exploration
2. Young Professionals of Milwaukee Celebrates Its Third Birthday, Looks To The Future
3. Internet Scout celebrates 10 years on web, eyes new project launch
4. Farm Aid celebrates 20-year journey, heads back to Illinois roots
5. UW Office of Corporate Relations Celebrates Early Accomplishments
6. Its All Fun And Games in Madison - Raven Software Celebrates 15 Anniversary
7. Merge files financial reports by market opening
8. RFID pilot project aims to improve blood banks
9. Pilot fund brings capital to Eau Claire area innovations
10. National $100m pilot program to begin mapping cancer genome
11. Milwaukee health provider network pilots software plan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... BOSTON (PRWEB) , ... October 12, 2017 , ... ... name for two-dimensional representations of a complex biological network, a depiction of a ... a big mess,” said Dmitry Korkin, PhD, associate professor of computer science at ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... Market with the addition of its newest module, US Hemostats & Sealants. , ... thrombin hemostats, absorbable hemostats, fibrin sealants, synthetic sealants and biologic sealants used in ...
(Date:10/11/2017)... ... October 11, 2017 , ... The ... context, enabling overexpression experiments and avoiding the use of exogenous expression plasmids. The ... transformative for performing systematic gain-of-function studies. , This complement to loss-of-function studies, ...
(Date:10/11/2017)... -- VMS BioMarketing, a leading provider of patient support solutions, has ... (CNE) network, which will launch this week. The VMS CNEs ... professionals to enhance the patient care experience by delivering peer-to-peer ... care professionals to help women who have been diagnosed and ... ...
Breaking Biology Technology:
(Date:4/24/2017)... , April 24, 2017 Janice ... partner with  Identity Strategy Partners, LLP (IdSP) , ... or without President Trump,s March 6, 2017 ... Entry , refugee vetting can be instilled with greater ... (Right now, all refugee applications are suspended by ...
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market by Solution ... Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast to 2022", ... 14.30 Billion in 2017 to USD 31.75 Billion by 2022, at a ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), Biometrics, Card-Based ... & Logistics, Government & Public Sector, Utilities / Energy ... Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality & ... for a definitive report on the $27.9bn Access Control ... ...
Breaking Biology News(10 mins):